Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
第一作者:
Masayuki,Shiseki
第一单位:
Department of Hematology, Tokyo Women's Medical University, 8-1 Kawadacho, Shinjuku-ku, Tokyo, 162-8666, Japan. shisekim@dh.twmu.ac.jp.
作者:
主题词
成年人(Adult);老年人(Aged);女(雌)性(Female);融合蛋白质类, bcr-abl(Fusion Proteins, bcr-abl);基因表达调控, 白血病(Gene Expression Regulation, Leukemic);人类(Humans);杀伤细胞, 天然(Killer Cells, Natural);白血病, 髓系, 慢性, BCR-ABL阳性(Leukemia, Myelogenous, Chronic, BCR-ABL Positive);白血病, 髓样, 慢性期(Leukemia, Myeloid, Chronic-Phase);男(雄)性(Male);中年人(Middle Aged);突变(Mutation);蛋白激酶抑制剂(Protein Kinase Inhibitors);治疗结果(Treatment Outcome)
DOI
10.1007/s10147-017-1141-y
PMID
28550414
发布时间
2018-12-02
- 浏览6
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文